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Summary All patients with carcinoma of the breast seen in this Unit since 1970 were reviewed to study the
incidence, prognosis, morbidity and response to treatment of bone metastases. The biological characteristics
of the primary tumour were compared in patients relapsing first in bone or liver.
Sixty-nine percent of patients dying with breast cancer had bone metastases and bone was the commonest
site of first distant relapse. Bone relapse was more common in receptor positive or well differentiated (grade
1) tumours.
The median survival was 24 months in those with disease apparently confined to the skeleton compared
with 3 monlhs after fiist relapse in liver.
Ten percent of patients with breast cancer developed hypercalcaemia. All had metastatic disease and 85%
had widespread skeletal involvement. Fifteen percent of patients with disease confined to the skeleton
developed hypercalcaemia.
The response in bone to primary endocrine therapy, and chemotherapy, was apparently less than the
overall response achieved. A large proportion had apparently static disease reflecting the insensitivity of the
UICC assessment criteria. The duration of survival in these patients was similar to responding patients,
suggesting a tumour response may occur in the absence of discernable radiological evidence of healing.
The majority of patients with advanced breast cancer have
evidence of skeletal metastases by the time of death
(Galasko, 1981). Palliation of symptoms, control of the
disease and evaluation of specific therapy are important
issues in these patients. Bone metastases may remain
asymptomatic but pain is common and hypercalcaemia,
pathological fractures and leuco-erythroblastic anaemia may
occur.
Breast cancer has a variable and often long clinical course
and patients with bone metastases in particular frequently
have a protracted illness. Although premature death is
inevitable, remissions are frequent and patients usually
require palliative therapy - local radiotherapy and specific
systemic treatment - for many months or years.
Evaluating response in bone metastases to systemic
therapy is often difficult. Objective assessment of response
by UICC criteria (Hayward et al., 1977) requires radiological
evidence of healing of lytic disease. This may not be
apparent for 4-6 months and is not a direct reflection of
changes in the tumour load. Clinical trills using UICC
criteria have usually reported lower response rates for bone
than the overall response rate achieved by treatment
reflecting the insensitivity of assessment methods (Coleman
& Rubens, 1985).
During the past 15 years several thousand patients with
breast cancer have been treated in this Unit and we report
here our experience of the problems caused by bone
metastases. Information is presented on clinical course,
associated morbidity and the impact of systemic therapy in
palliation. Tumour characteristics associated with metastatic
disease in bone are analysed and a comparison is made with
patients with liver metastases who usually have more
aggressive disease of shorter duration.
Patients and methods
A retrospective analysis of all patients with histologically
proven carcinoma of the breast attending this Unit since
1970 has been made. Defined sub-sets have been selected to
enable analysis of incidence, morbidity, prognosis and
response to treatment of bone metastases and review the
biological characteristics of the primary tumour as listed
below.
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Incidence ofmetastases
Five hundred and eighty-seven patients dying during the
period 1979-1984 were studied to determinerthe incidence of
bone metastases and visceral disease. Additionally, 2240
patients presenting to this Unit over the past 10 years with
primary breast cancer were analysed to ascertain the
distribution and relative frequency of first relapse.
Survival, complications and course afterfirst relapse
A comparison of survival has been made in 498 patients with
first evidence of metastatic disease in the skeleton and 80
with first relapse in liver since 1975.
Analysis of subsequent complications and the distribution
of subsequent relapse at other sites was assessed in the 498
patients with first relapse in bone.
Tumour characteristics
A comparison of steroid receptor status and histological
grade (infiltrating ductal tumours only) was made between
patients with first relapse in bone and those developing liver
metastases. Because first relapse in the liver is unusual, and
receptor status and histological grading were not always
known, all patients developing liver disease, at any time,
were selected for these comparisons.
Hormonal status
Oestrogen receptor (ER) status was measured in 150/498
patients with first relapse in bone and 75 with relapse in the
liver. Progesterone receptor (PgR) status was measured in
110 patients with first relapse in bone and 60 with relapse in
the liver. Steroid receptor analysis was by the method of
King et al. (1979). A value >5 fmol mg- 1 cytosol protein
was considered positive.
Histological grading of the primary tumour using the
method of Bloom and Richardson (1957) was known in 861
patients with metastatic disease. Ninety-five had grade I (well-
differentiated), 464 grade 2 (intermediate differentiation),
and 302 grade 3 (poorly differentiated) tumours.
Response to treatment
A comparison of overall response to treatment with that in
bone was made in 183 patients receiving primary endocrine
therapy, of whom 112 had bone metastases, and 126
patients, all with skeletal involvement, receiving a variety of
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chemotherapy regimens. The time to progression and
survival of patients with responding, static and progressive
disease were compared by Mantel-Cox log-rank analysis.
Assessment of response was by UICC criteria (Hayward
et al., 1977).
Hypercalcaemia
Hypercalcaemia was identified in 147 patients seen in this
Unit since 1975. The distribution of metastatic disease in
these patients, the frequency of skeletal involvement, and
prognosis have been assessed. Skeletal disease was considered
to be widespread if 5 or more foci of increased tracer uptake
were visible on bone scan with radiological confirmation of
at least one lesion. Minimal skeletal involvement implied
either lack of radiological confirmation or fewer than five
lesions identifiable on the bone scan. The incidence of
hypercalcaemia was determined in 1049 patients with breast
cancer who died in the decade 1975-1984.
Management ofmetastatic bone disease
A full blood count, biochemical screen, and chest radiograph
had been performed in all patients. Radionuclide bone scans
with technetium labelled methylene diphosphonate were
performed in all patients whenever progressive disease was
suspected. Appropriate radiographs were taken of areas of
abnormal tracer uptake. Radionuclide liver scans were
performed in patients with hepatomegaly or liver function
abnormality.
Various systemic treatments have been used during the
time period of this study. These have followed a logical
sequence based on the knowledge of three variables. These
are: (1) the extent, pattern and aggressiveness of the initial
presentation of metastatic disease; (2) the menopausal status
of the patient; (3) the hormone receptor status of the
tumour. Hormone treatment has been the preferred initial
treatment, chemotherapy being used for patients failing to
respond to, or relapsing after, endocrine therapy. Exceptions
to this are patients with aggressive visceral disease and those
with hormone receptor negative tumours when cytotoxic
chemotherapy is the initial treatment ofchoice (Figure 1).
Additional treatments were used for complications of bone
metastases. Hypercalcaemia was initially treated by intra-
venous rehydration with normal saline. Patients becoming
normocalcaemic or remaining only mildly hypercalcaemic
commonly received oral phosphates to maintain control.
Those remaining hypercalcaemic were, until recently, treated
with mithramycin or calcitonin to inhibit bone resorption,
but now our present preferred agent for control of hyper-
calcaemia is 3 amino,l,hydroxypropylidene-l,l-bisphosphonate
(APD) (Coleman & Rubens, 1986).
To treat, or to reduce the risk of pathological fracture of a
long bone, internal fixation followed by radiotherapy was
performed. This usually relieved pain and provided optimum
conditions for callus formation and bony union. Spinal cord
compression was treated by surgical decompression if the
signs were rapidly progressing, but radiotherapy was
preferred for slowly progressing, previously non-irradiated
sites of compression. Bone marrow infiltration causing leuco-
erythroblastic anaemia often occurred late in the course of
the disease and, when it had become resistant to hormones,
treatment was by cautious low dose chemotherapy and
haematological support.
Results
Incidence andprognosis ofbone metastases
Bone was the most common site of metastatic disease. Four
hundred and eighty-five of 587 (69%) patients dying with
breast cancer in the 5 year period 1979-84 had radiological
evidence of skeletal metastases before death. In comparison
158 (27%) had lung metastases, and 157 (27%) liver
metastases.
Bone was also the most common site of first distant
relapse. In the past ten years 2240 patients have presented to
this Unit with primary breast cancer. Six hundred and
eighty-one (30%) have relapsed after a median follow-up of
nearly 5 years. Two-hundred and forty-five relapses (36%)
were classified as local, 395 (58%) as distant and 41 (6%)
concurrent local and distant. One hundred and eighty-four
patients relapsed first in bone (47% of all first distant
relapse). Table I shows the distribution and relative
frequency of first relapse.
The mean age of patients with first relapse in either bone
or in liver was 57 years (range 29-79 and 29-78 years in
bone and liver respectively). Thirty-one per cent with bone
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Table I Distribution and frequency of first relapse in 2240 patients presenting with primary breast
cancer
Distant
Site Locati' BoIIe s(ofi tissue LuInIg Pleura LiVte Braini Other
Number of
patients 245 184 75 46 30 19 6 35
/0 total study
population 11 8 3 2 1 1 0.3 1
" patients with
any relapse
(local and distant) 36 24 11 7 4 3 1 4
. patients with
distant relapse 47 19 12 8 5 2 9
'Local relapse defined as recurrence in ipsilateral
supraclavicular lymph nodes.
relapse and 33% with liver relapse were premenopausal. The
median disease-free interval before first relapse in either bone
or liver was identical at 20 months (range 0-120 for bone
and 0-91 months for liver).
The median duration of survival in 498 patients with first
relapse in bone was 20 months. In 253 patients with
metastatic disease apparently confined to the skeleton the
median duration of survival was 24 months. The median
duration of survival after first relapse in liver was only 3
months. (Figure 2).
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Figure 2 Survival after first relapse in bone or liver.
First relapse in bone was identified in 498 patients. Two
hundred and forty-five (49%) subsequently relapsed at other
sites. One hundred and forty-five (29%) developed one or
more of the principal complications of bone destruction;
hypercalcaemia, pathological fracture or spinal cord
compression. (Table II).
Tumour characteristics
Table III compares ER and PgR in patients with first relapse
in bone and liver metastases (not necessarily first site of
relapse). First relapse in bone was more common than the
development of liver metastases in ER positive (P= <0.001)
and PgR positive tumours (P= <0.05). Spread to the liver
was more likely from ER and/or PgR negative tumours.
Table IV compares the histological grade of the primary
tumour in patients with bone metastases and those with
breast or mastectomy scar, or ipsilateral axillary or
Table II Subsequent metastatic spread and
complications after first relapse of disease in
bone (n =498)
Site complication No. %
Bone only 253 51
Soft tissue 95 19
Liver 94 19
Pleura 78 16
Lung 72 14
Brain 20 4
Hypercalcaemia 86 17
Pathological fracture 78 16
Spinal cord compression 13 3
Table IIl Comparison of hormone receptor status of
the primary tumour in patients with first relapse in
bone and relapse in liver (first or subsequent)
Bonie Liver
No. % No. %
ER+ '120 (80) 44 (59) P= <0.001
ER- 30 (20) 31 (41)
PgR+ 66 (60) 26 (43) P= <0.05
PgR- 44 (40) 34 (57)
ER+PgR+ 62 (57) 20 (34) P= <0.01
ER+PgR- 27 (25) 15 (25)
ER -PgR + 4 (4) 5 (8)
ER-PgR- 16 (15) 19 (32) P= <0.01
'ER + and PgR + = > 5fmol mg- cytosol protein;
ER -and PgR-= < 5fmol mg- ' cytosol protein.
visceral disease. Bone metastases were more common with
well-differentiated tumours. Fifty-seven of 95 (60%) of
patients with grade 1 and 120/302 (40%) with grade 3
tumours developed bone metastases (P = <0.05). First
relapse in bone was also more common from well
differentiated tumours. Liver metastases were more common
in poorly differentiated tumours but this difference was not
significant. The development of either liver or lung
metastases (visceral disease) at any time was related to
histological grade. Twenty of 95 (21 %) of patients with
grade I and 124/302 (410%) with grade 3 tumours developed
visceral disease (P= <0.001).
Response to sySstemic treatment
Table V shows the response to primary endocrine treatment
of 183 patients with advanced breast cancer. The overall
response rate (complete and partial responses) was 35%. One
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Table IV Histological grade of the primary and the distribution
relapse
of subsequent metastatic
GraIdILe I Grade 2 Gralde 3
N =95 N =464 N=302
No. I0( No. 0 No. 0
Bone rnetastases at
any time
First relapse in bone
Liver metastases
at any time
Visceral metastases
at any time
(liver and/or lung)
57 (60) 223 (48) 120 (40) 1 vs. 2
I vs.3
2 vs. 3
37 (39) 155 (33) 84 (28) 1 is. 2
I us.3
2 vs. 3
14 (13) 69 (15) 66 (22) 1 vs. 2
1 us. 3
2 us. 3
20 (21) 129 (28) 124 (41) 1 us. 2
Ii's.3
2 vs. 3
Table V Overall response and response in bone to primary endocrine therapy
CR PR NC PD NA
0 ii 0 11 % 11 % n %
Overall response 10 (5) 56 (30) 42 (23) 50 (27) 25 (14)
(all patients)
n = 183
Overall response 1 (1) 34 (31) 31 (28) 38 (34) 8 (7)
(bone metastases
patients)
oI = 112
Response in bone 0 20 (18) 35 (31) 30 (27) 27 (24)
71= 112
CR=complete response, PR=partial response, NC no change, PD=progressive disease,
NA=not assessable.
whom the overall response rate was 32%, but response in
bone only 18%. The rate of progression overall and in bone
was similar at 27%. Apparently static disease in bone was
common (31%) and 24% of bony sites were unassessable,
because of either sclerotic appearance on X-ray, rapid extra-
skeletal progression, or lack of follow-up.
Sixty-eight patients had both osseus and non-osseus
metastases. Fourteen of 68 (21%) of the former and 27/68
(40%) of the latter showed objective response. The response
rate in non-osseus sites was significantly higher (P= <0.02).
Similarly response in bone to chemotherapy appeared less
common than the overall response. Thirty-seven of 126
(29%) patients, all with bone metastases, treated with
combination chemotherapy achieved complete or partial
response. Response in bone was less frequent with 18%
showing radiological evidence of healing (Table VI). A high
proportion of patients (47%) in this series also appeared to
have static bone disease.
The survival of patients with bone metastases receiving
primary endocrine therapy is shown in Figure 3. Responding
patients have the best prognosis with a median duration of
survival which exceeds 30 months compared with 7 months
in non-responders (P= <0.001). There is no significant
difference in survival between responding patients and those
with static disease although the trend is in favour of those
showing objective response. This suggests that a tumour
response may occur in the absence of discernable
radiological evidence of healing.
Mor-bidity c aused by bone metastases
Hypercalcaemia is a common complication of advanced
breast cancer. One hundred and one of 1049 (10%) patients
dying with breast cancer in the period 1975-84 developed
hypercalcaemia. All patients with hypercalcaemia had
Table VI Overall and bone response to chemotherapy (all typesa) in 126 patients
with bone metastases
PR NC PD NA
CR
1a 11 0 n 01 ° n
Overall response 0 36 (29) 42 (33) 28 (22) 20 (16)
Bone response 0 23 (18) 59 (47) 11 (9) 33 (26)
CR =complete response, PR =partial response, NC = no change, PD progressive
disease, NA= not assessable.
'Regimens included adriamycin + vincristine, CMF (cyclophosphamide,
methotrexate, 5 fluorouracil), mitomycin C+ vinblastine, and mitozantrone.
P= <0.05
P= <0.001
P= <0.05
NS
P= <0.05
NS
NS
NS
NS
NS
P= <0.001
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Figure 3 Survival from the start of primary endocrinc trecatmcnt
in patients with bone metastases (n= 112) for each response
category, partial response (PR), no change (NC) and progressive
disease.
Table VII Incidence of bone and liver metastases in
patients with hypercalcaemia and breast cancer (n
= 147)
Skelet(al involvement
Widlespr-etad LimiIitied
Wit/h liver Wiili Iiler
Tottil oiietatstases Tottil metaslases
No. No. No. No.
125 85 53 42 22 15 15 68
metastatic disease. One hundred and twenty-five of 147
(85%!o) patients with hypercalcaemia had evidence of multiple
bone metastases. Twenty-two of 147 (15%) had minimal or
no evidence of skeletal involvement identified by either
radionuclide bone scan or X-ray.
Liver metastases were identified before or at the time of
hypercalcaemia in 68/147 patients (46%). Liver involvement
was more common in patients with little or no skeletal
involvement (P<0.05) (Table VII). Eighty-six of 498 (17%)
of patients with first relapse in bone developed hyper-
calcaemia. In those with metastatic disease confined to the
skeleton 15% subsequently became hypercalcaemic,
compared with 31% of 94 patients who had additional
spread to the liver (P<0.001). Patients with hypercalcaemia
have a poor prognosis despite active treatment. The median
survival after hypercalcaemia is 3 months (range 0-56
months) and was similar in patients with or without liver
metastases.
Pathological fracture of a long bone occurred in 78/498
(16%) patients after first relapse in bone. The median
duration of survival after fracture was 12 months (range 0-
66 months). Thirteen of 498 developed spinal cord
compression with a median survival of 3 months (range 0-26
months) after this complication.
Discussion
Bone metastases are common in advanced breast cancer and
the 69% incidence of radiologically confirmed skeletal
metastases here is in accordance with the 47-85% incidence
reported in autopsy series (Gelasko, 1981). Lung or liver
metastases were each identified before death in 27% of
women dying with breast cancer. This however is less than
the 57-77% and 50-71% incidence of disease in lung and
liver respectively reported in autopsy series (Di Pietro ct a/.,
1976) indicating relatively frequent asymptomatic disease aIt
these sites as well as reflecting the insensitivity of clinical and
imaging techniques for detecting disease in these organs.
Bone is also the commonest site of first distant relapse of
breast cancer (McNeil, 1984). In this study bone was the first
site of distant relapse in 47% and viscera (liver, lung, pleura)
in 25%. Despite the relative frequency of bone relapse this
occurred in only 8% of 2240 patients presenting to this Unit
with primary breast cancer. This low incidence in an
unselected population helps explain why routine bone
scanning in the follow-up of early breast cancer is not cost
effective (Lee, 1985).
Age and disease free interval were similar in patients with
first relapse in either bone or in liver. Relapse in liver was
not more common in pre-menopausal patients despite the
tendency for lower receptor values in this group (Croton et
al., 1981). Metastatic bone disease, unlike liver disease,
frequently followed a protracted clinical course. The median
duration of survival was 24 months in patients with disease
apparently confined to the skeleton.
This study confirms that bone metastases are more
common in well differentiated receptor positive tumours,
while liver metastases are more frequent with receptor
negative anaplastic tumours (Elston et al., 1980).
Clinical trials in the treatment of breast cancer using the
UICC criteria of response have usually reported lower
reponse rates for bone lesions than the overall response
(Stewart et al., 1982). Possibly this could be a true
phenomenon if bone metastases are biologically different and
relatively refractory to treatment, but it seems more likely
that the difference is apparent rather than real because of the
insensitivity of assessment methods. Indeed the association
between bone metastases and receptor positive, well
differentiated tumours would predict a high response rate.
This underestimation of response to both primary
endocrine therapy and chemotherapy was also seen in this
study. The incidence of progressive disease was similar, but
the proportion of patients with non-assessable or apparently
stable disease was higher in bone. Survival from the start of
endocrine treatment was similar in patients with either
objective response or stable disease.
We are currently evaluating alternative response criteria
including radionuclide bone scanning, biochemical
parameters of bone metabolism and subjective assessment.
Preliminary results show that prediction of objective
response within 3-4 weeks of starting treatment is possible
(Coleman et al., unpublished data).
Morbidity from bone metastases was common. Twenty-
nine percent of patients with first relapse in bone
subsequently developed one or more of the major compli-
cations of bone destruction, hypercalcaemia, pathological
fracture and spinal cord compression. The prognosis of
patients with hypercalcaemia was poor with a median dura-
tion of survival of 3 months but prolonged remissions up
to 56 months are seen. Better prediction of impending
pathological fracture and early orthopaedic intervention
might reduce the frequency of this unpleasant complication.
This review of a single Unit's large experience of patients
with bone metastases treated by a logical sequence of
treatments has presented data on various clinical and
pathological aspects of metastatic bone disease. It has
confirmed the clinical importance of bone metastases, the
long and usually symptomatic clinical coursc, the
.1
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relationship between tumour characteristic and sites of
metastatic disease, and the difficulties in assessing response
to systemic therapy. New approaches to treatment and more
accurate methods of assessment are needed to improve
management.
We wish to thank Prof. M.N. Maisey and Dr 1. Fogelman for
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analyses, Dr R. Millis for histology and grading of tumours and Mr
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